Effect of an oral inmunoenhanced formula on sarcopenia and quality of life in ambulatory patients with cancer
Nutrición Hospitalaria · 2025
DOI: 10.20960/nh.05654 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrición Hospitalaria, 2025. Verfasst von Daniel de Luis und 3 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario. Centro de Investigación de Endocrinología y Nutrición. Facultad de Medicina. …. Hauptthemen laut MEDLINE: Sarcopenia, Quality of Life, Neoplasms, Dietary Supplements. Die Arbeit nennt 38 Literaturangaben.
Abstract (Originalsprache)
Background: patients with cancer are a group of high risk of malnutrition and sarcopenia. Inmunoenhanced oral nutritional supplements (ONS) can improve this complex situation. Objective: the objective of our study was to assess the effectiveness of an inmunoenhanced oral nutritional supplements (ONS) on sarcopenia and quality of life (QoL) in ambulatory patients with cancer and malnutrition. Material and methods: 158 ambulatory patients with cancer were recruited. A biochemical, anthropometric, impedance measurement, nutritional survey, muscle ultrasound and EQ5D quality of life test were performed before and after 12 weeks of intervention with 2 bricks per day of an immunoenhanced ONS. Results: the mean age was 69.2 ± 10.9 years (n = 158). At baseline, 43.7 % were classified as severe malnutrition with GLIM criteria; following the intervention, 33.7 % were reclassified as severe malnutrition status (p = 0.013). After dietary intervention, handgrip strength (1.7 ± 0.3 kg; p = 0.02), proteins (0.7 ± 0.2 g/dL; p = 0.01), albumin levels (0.8 ± 0.2 g/dL; p = 0.03), skeletal muscle index (5.4 ± 0.1 kg/m2; p = 0.01), appendicular skeletal mass (3.2 ± 0.3 kg/m2; p = 0.02) and appendicular skeletal mass index (2.5 ± 0.3 kg/m2; p = 0.01) improved. At the beginning of the study, 29.1 % of the patients presented according to the EWGSOP2 criteria, which decreased to 20.9 % after nutritional treatment (p = 0.01). The overall EQ-5D index score did not demonstrate a significant improvement following 12 weeks of supplementation. Analysis of the EQ-5D dimensions showed a significant improvement in the percentages (“no problems”) of mobility dimension and usual activities dimensions. Conclusions: the use of an inmunoenhanced ONS in real-world life study with patients with cancer shows a beneficial effect on nutritional parameters, sarcopenia and quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Servicio de Endocrinología y Nutrición. Hospital Clínico Universitario. Centro de Investigación de Endocrinología y Nutrición. Facultad de Medicina. Universidad de Valladolid. Instituto de Investigación Biosanitaria de…
Zitieren
APA
de Luis, D., Primo, D., Izaola, O., & López Gomez, J. J. (2025). Effect of an oral inmunoenhanced formula on sarcopenia and quality of life in ambulatory patients with cancer. Nutrición Hospitalaria. https://doi.org/10.20960/nh.05654
Vancouver
de Luis D, Primo D, Izaola O, López Gomez JJ. Effect of an oral inmunoenhanced formula on sarcopenia and quality of life in ambulatory patients with cancer. Nutrición Hospitalaria. 2025. doi:10.20960/nh.05654
BibTeX
@article{deLuis2025,
author = {de Luis, Daniel and Primo, David and Izaola, Olatz and López Gomez, Juan José},
title = {Effect of an oral inmunoenhanced formula on sarcopenia and quality of life in ambulatory patients with cancer},
journal = {Nutrición Hospitalaria},
year = {2025},
doi = {10.20960/nh.05654}
}
EUVIMED